France

Nicox SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial

Lead Product(s): NCX 470

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Ocumension Therapeutics

Deal Size: $165.0 million Upfront Cash: Undisclosed

Deal Type: Agreement March 11, 2020

Details:

Nicox will conduct both of its planned Phase 3 clinical trials, Mont Blanc and Denali, as multi-regional clinical trials in U.S. and China.

Nicox SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Nicox’s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for NCX 470 Phase 3 Program in Glaucoma

Lead Product(s): NCX 470

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 05, 2020

Details:

NCX 470 demonstrated both statistical non-inferiority and superiority to latanoprost, the U.S. market leader in prostaglandin analog prescriptions.

Nicox SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Nicox Receives Formulation Patent Extending NCX 470 U.S

Lead Product(s): NCX 470

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2020

Details:

NCX 470 is covered by a composition of matter patent until 2029, which is potentially eligible for up to a 5-year patent term extension based on the period of regulatory review.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Nicox SA

Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial

Nicox SA

Nicox’s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for NCX 470 Phase 3 Program in Glaucoma

Nicox SA

Nicox Receives Formulation Patent Extending NCX 470 U.S